Parcion Private Wealth LLC Makes New Investment in Boston Scientific Corporation $BSX

Parcion Private Wealth LLC bought a new position in Boston Scientific Corporation (NYSE:BSX) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 15,577 shares of the medical equipment provider’s stock, valued at approximately $680,000.

Several other institutional investors have also recently bought and sold shares of the company. Perigon Wealth Management LLC bought a new stake in Boston Scientific during the 2nd quarter valued at approximately $883,000. Y Intercept Hong Kong Ltd grew its holdings in Boston Scientific by 148.8% in the 2nd quarter. Y Intercept Hong Kong Ltd now owns 1,120,331 shares of the medical equipment provider’s stock valued at $47,816,000 after buying an additional 670,060 shares during the last quarter. Wealthfront Advisers LLC acquired a new stake in Boston Scientific in the 2nd quarter valued at approximately $3,253,000. PensionDanmark Pensionsforsikringsaktieselskab increased its position in Boston Scientific by 9.9% in the 2nd quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 320,038 shares of the medical equipment provider’s stock worth $13,659,000 after buying an additional 28,961 shares during the period. Finally, Tocqueville Asset Management L.P. bought a new position in Boston Scientific in the 2nd quarter worth approximately $38,539,000. Institutional investors own 89.07% of the company’s stock.

Insider Activity at Boston Scientific

In other news, Director David Habiger acquired 2,100 shares of the stock in a transaction dated Wednesday, August 5th. The shares were acquired at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the transaction, the director owned 17,160 shares in the company, valued at approximately $816,644.40. This trade represents a 13.94% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Michael Mahoney bought 186,240 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The stock was purchased at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the purchase, the chief executive officer directly owned 1,590,024 shares of the company’s stock, valued at $76,845,859.92. This represents a 13.27% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have bought a total of 189,522 shares of company stock worth $9,157,810 in the last three months. 0.34% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

BSX has been the subject of a number of research analyst reports. TD Cowen lowered Boston Scientific from a “buy” rating to a “hold” rating and cut their price target for the stock from $56.00 to $46.00 in a report on Friday. BTIG Research lowered their price objective on shares of Boston Scientific from $56.00 to $49.00 and set a “buy” rating on the stock in a research note on Thursday. Needham & Company LLC dropped their target price on shares of Boston Scientific from $57.00 to $48.00 and set a “buy” rating on the stock in a research report on Wednesday. Truist Financial dropped their target price on shares of Boston Scientific from $57.00 to $51.00 and set a “buy” rating on the stock in a research report on Wednesday, October 14th. Finally, Sanford C. Bernstein cut their target price on shares of Boston Scientific from $54.00 to $49.00 and set an “outperform” rating for the company in a research note on Thursday. One investment analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, eight have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $61.43.

Boston Scientific Stock Down 1.8%

BSX stock opened at $41.93 on Friday. Boston Scientific Corporation has a twelve month low of $39.57 and a twelve month high of $105.65. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. The company has a market cap of $60.77 billion, a PE ratio of 17.77, a price-to-earnings-growth ratio of 1.03 and a beta of 0.58. The business’s 50-day simple moving average is $44.78 and its 200 day simple moving average is $56.88.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 EPS for the quarter, meeting the consensus estimate of $0.73. Boston Scientific had a return on equity of 18.73% and a net margin of 16.62%. The firm had revenue of $5.14 billion during the quarter, compared to analysts’ expectations of $5.09 billion. During the same quarter in the prior year, the firm posted $0.75 EPS. The company’s revenue for the quarter was up 1.4% on a year-over-year basis. On average, research analysts anticipate that Boston Scientific Corporation will post 3.17 earnings per share for the current year.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific exceeded third-quarter earnings expectations, while management continues to support its long-term growth strategy. An eight-day cyber outage reduced quarterly sales by approximately $150 million, suggesting some of the impact may be temporary. Boston Scientific: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Some analysts still see upside: Robert W. Baird raised its price target to $51, while UBS, BTIG Research and Sanford C. Bernstein retained buy or outperform-equivalent ratings, although each lowered its target. Analysts Revise Forecasts After Q3 Results
• Neutral Sentiment: Barclays and Wells Fargo both maintain equal-weight ratings with $45 price targets, indicating limited expected upside from current levels and a wait-and-see stance.
• Negative Sentiment: Boston Scientific cut its fiscal 2026 guidance below analyst expectations, and its fourth-quarter outlook points to weaker sales. Management expects full-year organic revenue growth of about 4%, while analysts see growth challenges extending into 2027. BSX Q3 Earnings Call Flags Growth Challenges
• Negative Sentiment: The cyber incident, weakness in electrophysiology and WATCHMAN heart-device products, and pricing pressure in China are raising concerns about near-term revenue growth and execution. Boston Scientific Faces Cyber Incident and Product Pressures
• Negative Sentiment: Several firms downgraded the stock, including TD Cowen, JPMorgan, Oppenheimer and Needham. TD Cowen cut its rating to hold and reduced its target from $56 to $46, while Zacks added BSX to its Strong Sell list. New Strong Sell Stocks for October 30th
• Negative Sentiment: Relative to Intuitive Surgical, Boston Scientific is viewed as having weaker earnings momentum and less attractive near-term growth, adding competitive pressure to the investment case. Intuitive Surgical vs. Boston Scientific

Boston Scientific Profile

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.